| | | |
|---|---|---|
| 1. | Record Nr. | UNINA9910968604203321 |
| | Titolo | Evolution of translational omics : lessons learned and the path forward / / Committee on the Review of Omics-Based Tests for Predicting Patient Outcomes in Clinical Trials; Board on Health Care Services; Board on Health Sciences Policy ; Christine M. Micheel, Sharyl J. Nass, and Gilbert S. Omenn, editors ; Institutes of Medicine of the National Academies |
| | Pubbl/distr/stampa | Washington, D.C., : National Academies Press, c2012 |
| | ISBN | 1-283-63640-9<br>0-309-22419-5 |
| | Edizione | [1st ed.] |
| | Descrizione fisica | 1 online resource (338 p.) |
| | Altri autori (Persone) | MicheelChristine<br>NassSharyl J<br>OmennGilbert S |
| | Disciplina | 572.33 |
| | Soggetti | Genomics - Technology<br>Genomics - Data processing<br>Genetic translation - Technology<br>Biomolecules - Analysis<br>Biomolecules - Data processing<br>Bioinformatics - Technology<br>Biotechnology<br>Data mining - Analysis |
| | Lingua di pubblicazione | Inglese |
| | Formato | Materiale a stampa |
| | Livello bibliografico | Monografia |
| | Note generali | Description based upon print version of record. |
| | Nota di bibliografia | Includes bibliographical references. |
| | Nota di contenuto | ""Front Matter""; ""Reviewers""; ""Acknowledgments""; ""Contents""; ""Boxes, Figures, and Tables""; ""Summary""; ""1 Introduction""; ""2 Omics-Based Clinical Discovery: Science, Technology, and Applications""; ""3 Best Practices for Omics-Based Test Validation Prior to Use for Patient Management Decisions in a Clinical Trial Setting""; ""4 Evaluation of Omics-Based Tests for Clinical Utility and Use""; ""5 Responsible Parties""; ""6 Lessons from the Case Studies""; ""Appendix A: Case Studies"" |

| | |
|---|---|
| | ""Appendix B: Gene Expression Based Tests Developed at Duke University and Used in Clinical Trials""""Appendix C: Introduction to Biomarkers""; ""Appendix D: Reporting Guidelines""; ""Appendix E: Committee Member and Staff Biographies""; ""Appendix F: Information Gathering Sessionsand Speakers""; ""Acronyms and Abbreviations""; ""Glossary"" |
| Sommario/riassunto | Technologies collectively called omics enable simultaneous measurement of an enormous number of biomolecules; for example, genomics investigates thousands of DNA sequences, and proteomics examines large numbers of proteins. Scientists are using these technologies to develop innovative tests to detect disease and to predict a patient's likelihood of responding to specific drugs. Following a recent case involving premature use of omics-based tests in cancer clinical trials at Duke University, the NCI requested that the IOM establish a committee to recommend ways to strengthen omics-based test development and evaluation. This report identifies best practices to enhance development, evaluation, and translation of omics-based tests while simultaneously reinforcing steps to ensure that these tests are appropriately assessed for scientific validity before they are used to guide patient treatment in clinical trials. |